Table I.
Baseline demographics | Placebo (n = 20) | rHDL (n = 20) | P value |
---|---|---|---|
Age | 72.8 ± 8.31 | 69.0 ± 11.99 | NS |
Men | 17 (85) | 12 (60) | NS |
Symptoms | |||
Amaurosis fugax | 1 (5) | 1 (5) | NS |
TIA | 10 (50) | 8 (40) | NS |
Stroke | 9 (45) | 11 (55) | NS |
Time (days) from index event to CEA | 17.8 ± 8.52 | 17.1 ± 7.10 | NS |
Risk factors | |||
Smokinga | 18 (90) | 13 (65) | NS |
Dyslipidemiab | 19 (95) | 16 (80) | NS |
Hypertensionc | 20 (100) | 20 (100) | NS |
Diabetesd | 4 (20) | 3 (15) | NS |
Previous CVA | 3 (15) | 2 (10) | NS |
IHDe | 6 (30) | 5 (5) | NS |
Antiplatelet agent | |||
Aspirin | 20 (100) | 20 (100) | NS |
Clopidogrel | 8 (40) | 5 (25) | NS |
Dipyridamole | 3 (15) | 4 (20) | NS |
Statins | |||
Simvastatin 40 mg | 18 (90) | 19 (95) | NS |
Atorvastatin 20 | 1 (5) | 0 (0) | NS |
Atorvastatin 40 | 1 (5) | 1 (5) | NS |
Data are expressed as number (percentage) or mean ± SD.
CABG, coronary artery bypass graft; CVA, cardiovascular accident; HMG Co-A, 3-hydroxy-3- methylglutaryl coenzyme A; IHD, ischaemic heart disease; NS, nonsignificant; TIA, transient ischemic attack.
Past or present history of smoking.
Fasting cholesterol level >5.0 mmol/L and/or use of HMG Co-A reductase inhibitor (statin).
Systolic blood pressure >160 mm Hg and/or diastolic blood pressure >90 mm Hg and/or use of antihypertensives.
Fasting glucose level >7 mmol/L or insulin and non–insulin-dependent diabetes requiring treatment including diet controlled.
Previous history of myocardial infarction/CABG and/or angina requiring treatment.